Approved by the Quality Standards Subcommittee on April 15, 2008; by the Therapeutics and Technology Assessment Subcommittee on December 17, 2007; by the Practice Committee on January 25, 2009; and by the AAN Board of Directors on March 25, 2009. This article is being published jointly/simultaneously by ILAE in Epilepsia and AAN in Neurology.
Management issues for women with epilepsy—Focus on pregnancy (an evidence-based review): II. Teratogenesis and perinatal outcomes
Report of the Quality Standards Subcommittee and Therapeutics and Technology Subcommittee of the American Academy of Neurology and the American Epilepsy Society
Version of Record online: 27 APR 2009
Wiley Periodicals, Inc. © 2009 International League Against Epilepsy
Volume 50, Issue 5, pages 1237–1246, May 2009
How to Cite
Harden, C. L., Meador, K. J., Pennell, P. B., Allen Hauser, W., Gronseth, G. S., French, J. A., Wiebe, S., Thurman, D., Koppel, B. S., Kaplan, P. W., Robinson, J. N., Hopp, J., Ting, T. Y., Gidal, B., Hovinga, C. A., Wilner, A. N., Vazquez, B., Holmes, L., Krumholz, A., Finnell, R., Hirtz, D. and Le Guen, C. (2009), Management issues for women with epilepsy—Focus on pregnancy (an evidence-based review): II. Teratogenesis and perinatal outcomes. Epilepsia, 50: 1237–1246. doi: 10.1111/j.1528-1167.2009.02129.x
- Issue online: 7 MAY 2009
- Version of Record online: 27 APR 2009
- Accepted February 24, 2009; Early View publication April 27, 2009.
- Antiepileptic drugs;
- Major congenital malformations;
- Apgar score;
- Small for gestational age
A committee assembled by the American Academy of Neurology (AAN) reassessed the evidence related to the care of women with epilepsy (WWE) during pregnancy, including antiepileptic drug (AED) teratogenicity and adverse perinatal outcomes. It is highly probable that intrauterine first-trimester valproate (VPA) exposure has higher risk of major congenital malformations (MCMs) compared to carbamazepine (CBZ), and possibly compared to phenytoin (PHT) or lamotrigine (LTG). It is probable that VPA as part of polytherapy and possible that VPA as monotherapy contribute to the development of MCMs. AED polytherapy probably contributes to the development of MCMs and reduced cognitive outcomes compared to monotherapy. Intrauterine exposure to VPA monotherapy probably reduces cognitive outcomes and monotherapy exposure to PHT or phenobarbital (PB) possibly reduces cognitive outcomes. Neonates of WWE taking AEDs probably have an increased risk of being small for gestational age and possibly have an increased risk of a 1-minute Apgar score of <7. If possible, avoidance of VPA and AED polytherapy during the first trimester of pregnancy should be considered to decrease the risk of MCMs. If possible, avoidance of VPA and AED polytherapy throughout pregnancy should be considered and avoidance of PHT and PB throughout pregnancy may be considered to prevent reduced cognitive outcomes.